- Home
- TS vs BIIB Comparison
TS vs BIIB Comparison
Compare TS & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TS
- BIIB
- Stock Information
- Founded
- TS 2001
- BIIB 1978
- Country
- TS Luxembourg
- BIIB United States
- Employees
- TS N/A
- BIIB N/A
- Industry
- TS Steel/Iron Ore
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- TS Industrials
- BIIB Health Care
- Exchange
- TS Nasdaq
- BIIB Nasdaq
- Market Cap
- TS 22.7B
- BIIB 19.9B
- IPO Year
- TS N/A
- BIIB 1991
- Fundamental
- Price
- TS $34.06
- BIIB $118.17
- Analyst Decision
- TS Strong Buy
- BIIB Buy
- Analyst Count
- TS 5
- BIIB 27
- Target Price
- TS $45.20
- BIIB $201.26
- AVG Volume (30 Days)
- TS 1.7M
- BIIB 1.5M
- Earning Date
- TS 04-30-2025
- BIIB 05-01-2025
- Dividend Yield
- TS 3.23%
- BIIB N/A
- EPS Growth
- TS N/A
- BIIB 26.39
- EPS
- TS 1.63
- BIIB 10.12
- Revenue
- TS $12,004,602,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- TS N/A
- BIIB N/A
- Revenue Next Year
- TS $1.72
- BIIB N/A
- P/E Ratio
- TS $10.01
- BIIB $11.69
- Revenue Growth
- TS N/A
- BIIB 1.59
- 52 Week Low
- TS $27.24
- BIIB $110.04
- 52 Week High
- TS $40.87
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- TS 50.23
- BIIB 42.08
- Support Level
- TS $32.97
- BIIB $115.25
- Resistance Level
- TS $33.93
- BIIB $125.34
- Average True Range (ATR)
- TS 0.70
- BIIB 3.42
- MACD
- TS 0.26
- BIIB 0.64
- Stochastic Oscillator
- TS 94.65
- BIIB 28.94
About TS Tenaris S.A.
Tenaris is one of the largest global producers of oil country tubular goods, which are used primarily in the construction of oil and gas wells. Its production facilities are located primarily in the U.S., Argentina, Mexico, and Italy. Tenaris' premium OCTG products are among the most trusted by oil companies for use in the most challenging applications, including deep-water offshore wells and horizontal shale wells.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.